C-reactive protein and hypertension

F G Hage1

  • 11] Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA [2] Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA.

Insights

C-reactive protein (CRP) is a key biomarker for cardiovascular disease and hypertension. Elevated CRP levels predict cardiovascular events and hypertension development, and CRP actively contributes to vascular dysfunction.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Biology
  • Hypertension Research

Background:

  • C-reactive protein (CRP) is a well-established biomarker for cardiovascular disease (CVD).
  • CRP levels are used to assess cardiovascular risk and guide therapy selection in intermediate-risk individuals.
  • The role of CRP in hypertension is increasingly recognized.

Purpose of the Study:

  • To review the multifaceted role of C-reactive protein (CRP) in the context of hypertension.
  • To explore CRP's association with hypertension-related vascular damage and cardiovascular outcomes.
  • To examine CRP's potential as a predictor of hypertension development and its direct role in vascular pathology.

Main Methods:

  • Review of existing literature on C-reactive protein (CRP) and hypertension.
  • Analysis of studies investigating CRP levels in hypertensive and normotensive individuals.
  • Examination of experimental data on CRP's direct effects on vascular function and remodeling.

Main Results:

  • In hypertensive individuals, CRP levels correlate with vascular stiffness, atherosclerosis, end-organ damage, and cardiovascular events.
  • Some antihypertensive drugs may reduce CRP levels independently of blood pressure effects.
  • Baseline CRP levels predict future hypertension development in normotensive individuals.
  • CRP actively contributes to endothelial dysfunction, vascular stiffness, and elevated blood pressure.
  • CRP is implicated in vascular and cardiac remodeling processes.

Conclusions:

  • C-reactive protein (CRP) is a significant biomarker and active participant in hypertension pathogenesis.
  • CRP's role extends beyond risk prediction to direct mediation of vascular dysfunction and remodeling.
  • Further research into CRP-mediated inflammatory pathways may reveal novel therapeutic targets for hypertension and related vascular diseases.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
769
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.8K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.8K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
891
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K